-
Statement
Incubate Comment in Response to the FTC’s Request for Comments on the Business Practices of PBMs
05.25.2022
Read Incubate's response to the FTC's Solicitation for Public Comments on the Business Practices of Pharmacy Benefit Managers and Their Impact on Independent Pharmacies and Consumers
-
Statement
Incubate Executive Director John Stanford Statement in Response to the Centers for Medicare & Medicaid Services’ Devastating Final National Coverage Determination for Certain Alzheimer’s Treatments
04.14.2022
See Executive Director John Stanford's statement on CMS' Final NCD on Alzheimer's disease and how this will affect the future of biopharmaceutical investment.
-
Statement
Incubate Letter in Opposition to MA S. 2774
04.07.2022
See Incubate's letter to the Massachusetts state legislature in opposition to S. 2774
-
Article
To Spend Less on Healthcare, Invest in More Medicines
04.05.2022
Read John Stanford and JF Formela's op-ed on how we can lower health costs by spending more on drugs.
-
Statement
Incubate Letter in Opposition to CT SB-13
03.29.2022
See Incubate's letter to Connecticut legislature opposing SB-13.
-
Statement
Gaurav Gupta Comment on the Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
02.10.2022
Incubate Advisory Council member Gaurav Gupta's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
-
Statement
Incubate Comment on the Proposed Decision Memo for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
02.10.2022
Executive Director John Stanford's comment on CMS's Proposed Decision for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
-
Article
CMS’s Devastating Blow to Seniors
02.09.2022
Read Incubate Advisory Council member Gaurav Gupta's op-ed on the CMS's decision to cover Alzheimer's drugs.
-
Statement
Moonshot Statement
02.02.2022
Read Incubate Executive Director John Stanford's statement on President BIden's Moonshot initiative.
-
Article
Investors Say Drug-Pricing Measure May Shift Incentives for Biotech Venture Funding
12.02.2021
A drug-pricing bill the House passed in November could affect which life-sciences startups venture-capital investors are likely to back.
-
Article
House passage of Build Back Better gets mixed reaction
11.22.2021
As investors in biotechnology and pharmaceuticals, we're alarmed by the potential consequences of the drug-pricing measure included in the Build Back Better Act, which just passed the House.
-
Statement
Leading Venture Capital Group Alarmed By Build Back Better Act’s Prescription Drug Provision
11.19.2021
John Stanford, Executive Director of Incubate, a coalition of America's early-stage life sciences investors, issued the following statement on congressional Democrats' passage of the Build Back Better Act
Resources
